Zimmer Biomet Holdings (NYSE: ZBH) shares plummeted 13.62% in pre-market trading on Wednesday following the release of its third-quarter results and a reduced forecast for 2025 organic sales growth. The medical device maker's stock took a significant hit as investors reacted to disappointing performance in international markets and a slight revenue miss.

For the third quarter of 2025, Zimmer Biomet reported adjusted earnings per share of $1.90, surpassing the analyst consensus estimate of $1.88. However, the company's quarterly sales of $2.001 billion narrowly missed the analyst consensus estimate of $2.005 billion. Despite the 9.7% year-over-year increase in revenue, the slight miss raised concerns among investors.

Adding to the downward pressure, Zimmer Biomet cut its 2025 organic revenue growth forecast, citing weakness in Latin America and emerging markets in Europe. The company lowered the upper end of its organic growth outlook to 4.0% from 4.5%, while maintaining the lower end at 3.5%. This adjustment, coupled with Barclays cutting its price target for Zimmer Biomet from $112 to $105, further fueled investor worries about the company's growth prospects. The sharp pre-market decline suggests that market participants are reassessing their expectations for the company's future performance in light of these developments.